Evidence map›Paper›PMID 36915253›Full record

ArticleCancer research and treatment2023

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.

So Heun Lee, Dae Wook Hwang, Changhoon Yoo, Kyu-Pyo Kim, Sora Kang, Jae Ho Jeong, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Do Hyun Park and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

So Heun LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dae Wook HwangDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Changhoon YooDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Kyu-Pyo KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sora KangDepartment of Hematology and Oncology, Chungnam National University Hospital, Daejeon, Korea.
Jae Ho JeongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dongwook OhDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Tae Jun SongDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Sang Soo LeeDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Do Hyun ParkDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dong Wan SeoDepartment of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jin-Hong ParkDepartment of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ki Byung SongDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jae Hoon LeeDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Woohyung LeeDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yejong ParkDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Bong Jun KwakDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Heung-Moon ChangDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Baek-Yeol RyooDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Song Cheol KimDepartment of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Asan Medical Center · KRUlsan College · KRUniversity of Ulsan · KRChungnam National University Hospital · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2021IT0008
6 · The paper itself

Abstract

purposeThe benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit of adjuvant chemotherapy in this patient population. Materials and Methods: This retrospective study included 218 patients with localized non-metastatic PDAC who received neoadjuvant FOLFIRINOX and underwent curative-intent surgery (R0 or R1) between January 2017 and December 2020. The association of adjuvant chemotherapy with disease-free survival (DFS) and overall survival (OS) was evaluated in overall patients and in the propensity score matched (PSM) cohort. Subgroup analysis was conducted according to the pathology-proven lymph node status.

resultsAdjuvant chemotherapy was administered to 149 patients (68.3%). In the overall cohort, the adjuvant chemotherapy group had significantly improved DFS and OS compared to the observation group (DFS: median, 13.8 months [95% confidence interval (CI), 11.0 to 19.1] vs. 8.2 months [95% CI, 6.5 to 12.0]; p < 0.001; and OS: median, 38.0 months [95% CI, 32.2 to not assessable] vs. 25.7 months [95% CI, 18.3 to not assessable]; p=0.005). In the PSM cohort of 57 matched pairs of patients, DFS and OS were better in the adjuvant chemotherapy group than in the observation group (p < 0.001 and p=0.038, respectively). In the multivariate analysis, adjuvant chemotherapy was a significant favorable prognostic factor (vs. observation; DFS: hazard ratio [HR], 0.51 [95% CI, 0.36 to 0.71; p < 0.001]; OS: HR, 0.45 [95% CI, 0.29 to 0.71; p < 0.001]).

conclusionAmong PDAC patients who underwent surgery following neoadjuvant FOLFIRINOX, adjuvant chemotherapy may be associated with improved survival. Randomized studies should be conducted to validate this finding.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantFluorouracilHumansIrinotecanLeucovorinNeoadjuvant TherapyOxaliplatinRetrospective StudiesFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinAdenocarcinomaAdjuvant chemotherapyFOLFIRINOXNeoadjuvant therapyPancreatic neoplasmsPrognosisPropensity score

Identifiers

PMID36915253
PMCPMC10372602
OpenAlexW4322502227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.